Sinovac Biotech ( Sinovac Biotech )

Sinovac Biotech

Sinovac Biotech's picture

inovac Biotech Ltd. is a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China.
inovac's commercialized vaccines include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza), Panflu (H5N1) and PANFLU.1 (H1N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.[1]

Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Sinovac Biotech press release, blog etc

04/27/2018 - 05:54 Sinovac Enters into Amendment to Amalgamation Agreement
04/27/2018 - 04:53 Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing
04/23/2018 - 13:01 Sinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department
04/19/2018 - 06:49 Sinovac Announces Preliminary Results of Phase III Trial on sIPV
03/27/2018 - 05:20 Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
03/15/2018 - 05:15 Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties
03/05/2018 - 20:35 Sinovac Announces Enhancement of Corporate Governance and Management of China Operating Entity
02/07/2018 - 05:40 Sinovac Holds 2017 Annual General Meeting of Shareholders
02/07/2018 - 05:34 Sinovac Provides Update on Going Private Transaction
12/29/2017 - 03:34 Sinovac Schedules 2017 Annual Meeting of Shareholders
12/22/2017 - 10:20 Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization
11/08/2017 - 20:24 Sinovac Biotech Announces Request Hearing before Nasdaq Hearings Panel
11/03/2017 - 17:37 Sinovac Biotech Announces Receipt of DelistingDetermination Letter fromNasdaq
09/25/2017 - 05:37 Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox
08/14/2017 - 05:01 Sinovac Biotech Announces Certain Updates Relating to Delayed Filing of Annual Report on Form 20-F
06/26/2017 - 11:37 Sinovac Biotech Ltd. Enters into Definitive Agreement for Going-Private Transaction
05/16/2017 - 12:47 Sinovac Biotech Announces Receipt of NASDAQ Letter
12/23/2016 - 07:52 Sinovac Responds to Recent Report